

Unique wound healing device with Norwegian salmon roe enters the market in 2019

Gry Lønne Eriksson, PhD, Chief Scientific Officer
DNB NXT, October 19th 2016

N



T

reGenics



THE PROBLEM



Basic wound care



Advanced wound care

The true costs of wound care are hidden

Dressings & other materials


Typically 15-20% of total cost

Nurse time

Typically 30-35% of total cost

Hospitalisation

Typically >50% of total cost



THE MARKET

Advanced wound care market:

- 34 bn NOK (4 bn USD) in 2016
- Strong (>14%) annual growth
- Expected to see a value of 5 bn USD by 2020



COMPETITION ADVANTAGES

- Few products with biological activity
- Most covering the wound, shielding from external detrimental factors
- Products on the market claiming efficacy beyond surface protection are extremely expensive;
- thus in limited use in the healthcare system

What the healthcare systems need:

affordable wound healing devices that accelerates healing of chronic and hard-to-heal wounds

Our product will fulfill this need




THE PRODUCT



Unfertilized salmon roe

↑
Collagen secretion
Cell migration
Hyaluronic acid secretion
Elastin production



Reepithelialization in burn wounds



Medical device for treatment of chronic and hard-to-heal wounds.

CE

CE marked class IIb in 2018


VERNEX®

- CE marked medical device class IIb in 2018




Regenics leads a development consortium with funding from **Eurostars and BIA (2015-2018)** - total budget: 27.6 mill NOK



Regenics employs a simple business model:



LEX® crude extract for cosmetics



VERNEX® wound healing device (CE)

The salmon roe technology is patented globally, and Regenics owns all IPR.

REVENUE FORECAST

	2016	2017	2018
Revenue	4.5 MNOK	5.4MNOK	9 MNOK
Net income	0.5 MNOK	0.5 MNOK	0.5 MNOK

RAISED TO DATE: 10.5 mill NOK (+ 21 MNOK public funding)

Current investors are private investors including founders, board members and management.

*Regenics seeks investment 15 mill NOK
- clinical efficacy trial*

Raising: 15 Million NOK

THE TEAM AND BOARD

 <p>Henrik Lund, Chief Executive Officer</p>	 <p>Christian Clemm, Chief Medical Officer</p>	 <p>Gry Lenne Eriksson, Chief Scientific Officer</p>	 <p>Tore Heldrup Rasmussen, MBA Chairman of the board Co-founder</p>	 <p>Prof. Philippe Collas, PhD Board member Co-founder</p>
 <p>Dominika Andrys, Research and Formulation Scientist</p>	 <p>Markus Heldrup, Production Manager</p>	 <p>Hege O'Wiid, Research Technician</p>	 <p>Harald Nordal, MSc, MBA Board member</p>	 <p>Runhild Gammelsæter, PhD Board member</p>
 <p>Mitchell Jones, Patent Attorney (US)</p>	 <p>Anne-Karine Hafian, CE marking/QA consultant</p>			

Very experience management team:

15-20 years pharma: Business
Clinical development
Regulatory, CE marking
Patents, IP (US)

WE OFFER

A unique opportunity to invest in a

- First in class medical device from Norwegian salmon industry
- EU funded project with a 27 mill NOK budget in a strong consortium

Proposal: 15 mill NOK in capital for clinical trial

www.regenics.no

reGenics 